Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Passage BIO, Inc. (PASG) · filed Sep 18, 2024

Accession no.
0000947871-24-000763
Filed
Sep 18, 2024, 6:38 PM ET
Trade date
Sep 16-18, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market sales total $146.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 000105595110% Owner
OrbiMed Capital GP VII LLCCIK 000176064810% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 16, 2024Common StockSSaleDisposed−63,100$0.74F1−$46,6947,970,900Indirect
Sep 17, 2024Common StockSSaleDisposed−111,400$0.73F2−$81,3227,859,500Indirect
Sep 18, 2024Common StockSSaleDisposed−25,631$0.73−$18,710.637,833,869Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.73 to a high of $0.78 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F2

Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $0.73 to a high of $0.75 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a securityholder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)